NDC 50090-7276-01 - Acyclovir
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 50090-7276
- Requested NDC
- 50090-7276-01
- Package NDCs from labels
- 50090-7276-0, 50090-7276-1, 50090-7276-01
- Manufacturer
- A-S Medication Solutions
- Effective date
- 2024-10-14
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Acyclovir - A-S Medication Solutions | A-S Medication Solutions | 2024-10-14 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 50090-7276-0 | Acyclovir | 90 in 1 BOTTLE | TABLET | 90 | 3 | |
| 50090-7276-1 | Acyclovir | 21 in 1 BOTTLE | TABLET | 21 | 3 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 50090-7276 | ACYCLOVIR TABLET [A-S MEDICATION SOLUTIONS] | 3 | Current NDC, 2 package rows | 20241015_b96e44ca-aa54-4a64-89f4-fb5a5932ceae.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 50090-7276-0 | EA - Each | 50090-7276 | d6da1847-493e-4267-b194-80a528bc79bb | 1 | 2024-11-05 |
| 50090-7276-1 | EA - Each | 50090-7276 | c7c8da91-03d8-473b-bdfc-1b6ea23c441f | 1 | 2024-11-05 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Acyclovir | ACYCLOVIR | YILING PHARMACEUTICAL, INC. | 8542495c-eef1-448b-abb5-83cb1ac589f7 | 2025-12-30 | Warnings, Adverse reactions | X4HES1O11F |
| Acyclovir | ACYCLOVIR | YILING PHARMACEUTICAL, INC. | 677edfd5-2d04-b932-e053-2a91aa0a26b0 | 2025-12-30 | Warnings, Adverse reactions | ANDA210401 197311 X4HES1O11F |
| Acyclovir | ACYCLOVIR | Chartwell Governmental & Specialty RX, LLC. | 2757bb30-3374-4e1b-b496-14874f7ec623 | 2025-12-23 | Warnings, Adverse reactions | X4HES1O11F |
| Acyclovir | ACYCLOVIR | Chartwell RX, LLC | 7d2a75a5-233f-46dd-9cb0-3918ea53e554 | 2025-12-18 | Warnings, Adverse reactions | X4HES1O11F |
| ACYCLOVIR | ACYCLOVIR | Aurobindo Pharma Limited | cfee4476-a3c9-4e0c-a235-c68c5d46931e | 2025-12-16 | Warnings, Adverse reactions | 197313 197311 X4HES1O11F |
| Acyclovir | ACYCLOVIR | Redpharm Drug | 37453bcd-e34e-5902-e063-6294a90a0245 | 2025-12-13 | Warnings, Adverse reactions | ANDA210401 197311 X4HES1O11F |
| Acyclovir | ACYCLOVIR | Chartwell RX, LLC | 8cd22728-34b4-4e55-8339-580138fe46d8 | 2025-12-09 | Warnings, Adverse reactions | ANDA210401 197313 X4HES1O11F |
| Acyclovir | ACYCLOVIR | Cadila Pharmaceuticals Limited | acef88f4-6456-4092-993f-27e1496097c7 | 2025-12-05 | Warnings, Adverse reactions | 197313 197311 X4HES1O11F |
| ACYCLOVIR | ACYCLOVIR | Aurobindo Pharma Limited | 37761c4f-4378-472e-a41b-6a1d40575cb7 | 2025-12-03 | Warnings, Adverse reactions | X4HES1O11F |
| acyclovir | ACYCLOVIR | Viona Pharmaceuticals Inc | e580b7e9-9060-43f5-9b58-33998078d7e4 | 2025-12-02 | Warnings, Adverse reactions | X4HES1O11F |
| Acyclovir | ACYCLOVIR | Advagen Pharma Limited | 6a9ea291-4ad5-48a8-8c08-5a17c8757549 | 2025-11-27 | Warnings, Adverse reactions | X4HES1O11F |
| acyclovir | ACYCLOVIR | Zydus Lifesciences Limited | 8d9fea43-6c04-40d7-8aac-398c2de2a558 | 2025-11-27 | Warnings, Adverse reactions | 197313 197311 X4HES1O11F |
| acyclovir | ACYCLOVIR | Zydus Pharmaceuticals (USA) Inc. | edb0cd28-ee57-4b60-be94-62c797fbf5e6 | 2025-11-27 | Warnings, Adverse reactions | 197313 197311 X4HES1O11F |
| acyclovir | ACYCLOVIR | Zydus Lifesciences Limited | 395cd839-21e1-43e2-a8ce-078f07bc7668 | 2025-11-22 | Warnings, Adverse reactions | X4HES1O11F |
| acyclovir | ACYCLOVIR | Apotex Corp. | 7fdeb609-24c4-5024-52c3-6a32bc7f3fcc | 2025-11-20 | Warnings, Adverse reactions | 197313 197311 X4HES1O11F |
| ACYCLOVIR | ACYCLOVIR | Apotex Corp. | 41bea43a-f58c-2c6f-4d31-406ceb456077 | 2025-11-17 | Warnings, Adverse reactions | X4HES1O11F |
| Acyclovir | ACYCLOVIR | Teva Pharmaceuticals USA, Inc. | 103f29b8-2c13-4917-a446-59d3246d48d1 | 2025-10-23 | Warnings, Adverse reactions | X4HES1O11F |
| acyclovir | ACYCLOVIR | NuCare Pharmaceuticals, Inc. | 41d5ae3e-51c0-263b-e063-6394a90a3312 | 2025-10-23 | Warnings, Adverse reactions | X4HES1O11F |
| Acyclovir | ACYCLOVIR | ATLANTIC BIOLOGICALS CORP. | 4032ce02-e2b3-d426-e063-6294a90ab6c9 | 2025-10-01 | Warnings, Adverse reactions | X4HES1O11F |
| Acyclovir | ACYCLOVIR | Sun Pharmaceutical Industries, Inc. | 962b2e1a-ba9d-4b39-b6d1-203947166482 | 2025-09-29 | Warnings, Adverse reactions | X4HES1O11F |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.